Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function.

M Mandal1, R Vadlamudi, D Nguyen

  • 1Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center-108, Houston 77030, USA.

The Journal of Biological Chemistry
|December 31, 2000
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nuclear shell structure governs short-range nucleon pairing.

Nature·2026
Same author

Search for Light Pseudoscalar Bosons, Pair-Produced in Higgs Boson Decays in the Four-Electron Final State in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

First Evidence for Mixing-Induced CP Violation in B_{s}^{0}→J/ψϕ(1020) Decays in pp Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

Observation of Suppressed Charged-Particle Production in Ultrarelativistic Oxygen-Oxygen Collisions.

Physical review letters·2026
Same author

Measurement of D^{0} Meson Photoproduction in Ultraperipheral Heavy Ion Collisions.

Physical review letters·2026
Same author

Observation of tWZ Production at the CMS Experiment.

Physical review letters·2026

Epidermal Growth Factor (EGF) receptor signaling drives cancer cell growth by increasing hnRNP K expression. Therapeutic antibodies targeting EGF receptors (EGFR) and HER2 block this pathway, inhibiting tumor progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Epidermal Growth Factor (EGF) family receptors regulate epithelial cell proliferation in normal and cancerous tissues.
  • Antireceptor blocking antibodies can suppress these processes.
  • Identifying genes modulated by these antibodies is crucial for therapeutic development.

Purpose of the Study:

  • To identify genes regulated by antireceptor blocking antibodies.
  • To investigate the role of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in EGF receptor signaling and breast cancer.
  • To evaluate the therapeutic potential of anti-EGFR and anti-HER2 antibodies.

Main Methods:

  • Differential display screening to identify modulated genes.
  • Treatment of human breast cancer cells with EGF, heregulin-beta1, and antireceptor antibodies (anti-EGFR C225, anti-HER2).

Related Experiment Videos

  • Xenograft studies in athymic mice with anti-EGFR monoclonal antibody.
  • Analysis of hnRNP K protein levels in breast cancer tissues of varying grades.
  • Overexpression studies of hnRNP K in breast cancer cells.

    • Main Results:

    • hnRNP K was identified as a gene modulated by antireceptor antibodies.
    • EGF and heregulin-beta1 increased hnRNP K mRNA and protein levels in breast cancer cells.
    • Anti-EGFR and anti-HER2 antibodies blocked EGF-mediated hnRNP K expression.
    • Anti-EGFR antibody treatment led to tumor xenograft regression and reduced hnRNP K levels in vivo.
    • Higher hnRNP K protein levels were observed in grade III vs. grade II breast cancer.
    • hnRNP K overexpression enhanced c-myc promoter activity, c-Myc protein levels, and anchorage-independent breast cancer cell growth.

    Conclusions:

    • EGF receptor family activity regulates hnRNP K expression in response to extracellular growth signals.
    • Therapeutic antibodies targeting EGFR and HER2 effectively block EGF-mediated hnRNP K expression and breast cancer cell proliferation.
    • hnRNP K is a key mediator in EGF receptor-driven breast cancer growth and represents a potential therapeutic target.